Timber Pharmaceuticals to Host Conference Call Discussing Positive Topline Results from Phase 2b CONTROL Study of Congenital Ichthyosis for Lead Asset, TMB-001

to be held on Monday, November 22nd at 10:00am ET

BASKING RIDGE, NJ – (NewMediaWire) – November 17, 2021 – Timber Pharmaceuticals, Inc.
(“Timber” or the “Company”) (NYSE American: TMBR), a
biopharmaceutical company focused on the development and commercialization of
treatments for rare and orphan dermatologic diseases, today announced that it
will host a conference call for investors and shareholders to discuss the
positive topline results from its recently completed Phase 2b CONTROL Study of
Congenital Ichthyosis for its lead asset, TMB-001. The call will be hosted by
Timber’s Chief Executive Officer, John Koconis, and Chief Medical Officer, Alan
Mendelsohn, M.D.

Conference Call Information

When: Monday, November 22nd at 10:00am ET

Dial in: (833) 685-0983 and ask to be joined into the
Timber Pharmaceuticals call.

There will also be a live webcast of the conference
call which can be accessed at:


For those unable to participate in the live conference
call, a replay will be archived and available on Timber’s website under the
Investor Relations tab at www.timberpharma.com .

About Timber Pharmaceuticals, Inc.

Timber Pharmaceuticals,
Inc. is a biopharmaceutical company focused on the development and
commercialization of treatments for rare and orphan dermatologic diseases. The
Company’s investigational therapies have proven mechanisms-of-action backed by
decades of clinical experience and well-established CMC (chemistry,
manufacturing and control) and safety profiles. The Company is initially
focused on developing non-systemic treatments for rare dermatologic diseases
including congenital ichthyosis (CI), facial angiofibromas (FAs) in tuberous
sclerosis complex (TSC), and other sclerotic skin diseases. For more
information, visit www.timberpharma.com.

Forward-Looking Statements

This press release
contains certain forward-looking statements within the meaning of Section 27A
of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of
1934 and Private Securities Litigation Reform Act, as amended, including those
relating to the Company’s product development, clinical and regulatory
timelines, market opportunity, competitive position, intellectual property
rights, possible or assumed future results of operations, business strategies,
potential growth opportunities and other statements that are predictive in
nature. These forward-looking statements are based on current expectations,
estimates, forecasts and projections about the industry and markets in which we
operate and management’s current beliefs and assumptions.

These statements may be
identified by the use of forward-looking expressions, including, but not
limited to, “expect,” “anticipate,” “intend,”
“plan,” “believe,” “estimate,” “potential, “predict,”
“project,” “should,” “would” and similar
expressions and the negatives of those terms. These statements relate to future
events or our financial performance and involve known and unknown risks,
uncertainties, and other factors which may cause actual results, performance or
achievements to be materially different from any future results, performance or
achievements expressed or implied by the forward-looking statements. Such
factors include those set forth in the Company’s Annual Report on Form 10-K for
the year ended December 31, 2020 as well as other documents filed by the
Company from time to time thereafter with the Securities and Exchange
Commission. Prospective investors are cautioned not to place undue reliance on
such forward-looking statements, which speak only as of the date of this press
release. The Company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information, future
events or otherwise.

For more information, contact:

Timber Pharmaceuticals, Inc.

John Koconis

Chairman and Chief Executive Officer


Investor Relations:

Stephanie Prince

PCG Advisory

(646) 863-6341


Media Relations:

Adam Daley

Berry &
Company Public Relations

(212) 253-8881